Usa covid-19 testing patient Coronavirus Usa

Coronavirus treatment: Gilead says remdesivir hit primary target in Covid-19 NIAID study

Reading now: 353
www.livemint.com

Gilead said data from NIAID study of its drug remdesivir showed the medication had met the primary endpoint in a trial of its effectiveness in treating coronavirus patient Gilead Sciences Inc.

said data from a US study of its drug remdesivir showed the medication had met the primary endpoint in a trial of its effectiveness in treating Covid-19.

The company said in a statement that it is aware of positive data emerging from the National Institute of Allergy and Infectious Diseases’ study of remdesivir for treating the disease caused by the novel coronavirus.

Gilead shares were halted, but the news appeared to lift the entire US stock market, with futures linked to major US indexes jumping after the company’s statement was issued.

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA